NANOG、ZEB1 和 EpCAM 生物标志物对浆液性卵巢癌预后的临床病理影响。
Clinicopathologic Impact of NANOG, ZEB1, and EpCAM Biomarkers on Prognosis of Serous Ovarian Carcinoma.
机构信息
Department of Pathology, Faculty of Medicine, Zagazig University, Egypt.
Department of Clinical Oncology, Faculty of Medicine, Zagazig University, Egypt.
出版信息
Asian Pac J Cancer Prev. 2023 Sep 1;24(9):3247-3259. doi: 10.31557/APJCP.2023.24.9.3247.
OBJECTIVES
Serous ovarian carcinoma (SOC) is a biologically heterogeneous with different genomic and molecular profiles, beside clinical response to the chemotherapy with subsequent in obstacles in starting unified, acceptable treatments and so we assess immunoexpression of Nanog, ZEB1, and EpCAM in SOC.
METHODS
In this study, the immunoexpression of Nanog, ZEB1, and EpCAM was studied in 60 cases of SOC. Overall survival (OS), disease-free survival (DFS) data and response to chemotherapy were analyzed.
RESULTS
NANOG was immunostained in 65% of the cases with a significant association with tumor grade, lymph node metastasis, and FIGO stage (p < 0.001 for each). ZEB1 showed moderate- high expression in 58.3% of the cases with significant up-regulation of ZEB1 expression with SOC grade, nodal metastasis, and SOC FIGO stage (p<0.001). EpCAM revealed high expression in 60% of the cases with significant association with higher grade, nodal metastasis, and advanced stage (p < 0.001 for each). Up-regulation of Nanog was significantly associated with response to chemotherapy, relapse, shorter OS and DFS (p < 0.001 for each). ZEB1 overexpression exhibited a significant association with response to chemotherapy (p= 0.012), relapse, shorter OS and DFS (p<0.001 for each). Moreover, the high EpCAM had a significant association with response to chemotherapy (p= 0.043), relapse (p < 0.001) shorter OS (p=0.006) and DFS (p< 0.001).
CONCLUSIONS
Up-regulation of Nanog and ZEB-1 and EpCAM perhaps promote an aggressive SOC with a high risk of relapse and unfavorable response to standard chemotherapy regimen.
目的
浆液性卵巢癌（SOC）是一种生物学异质性肿瘤，具有不同的基因组和分子特征。除了对化疗的临床反应不同之外，SOC 还存在着治疗障碍，因此我们评估了 SOC 中 Nanog、ZEB1 和 EpCAM 的免疫表达。
方法
在这项研究中，我们研究了 60 例 SOC 中 Nanog、ZEB1 和 EpCAM 的免疫表达。分析了总生存期（OS）、无病生存期（DFS）数据和化疗反应。
结果
NANOG 在 65%的病例中呈免疫染色，与肿瘤分级、淋巴结转移和 FIGO 分期显著相关（p<0.001）。ZEB1 在 58.3%的病例中呈中高表达，ZEB1 的表达与 SOC 分级、淋巴结转移和 SOC FIGO 分期显著上调相关（p<0.001）。EpCAM 在 60%的病例中呈高表达，与高级别、淋巴结转移和晚期显著相关（p<0.001）。Nanog 的上调与化疗反应、复发、较短的 OS 和 DFS 显著相关（p<0.001）。ZEB1 的过表达与化疗反应显著相关（p=0.012）、复发、较短的 OS 和 DFS 显著相关（p<0.001）。此外，EpCAM 高表达与化疗反应（p=0.043）、复发（p<0.001）、较短的 OS（p=0.006）和 DFS（p<0.001）显著相关。
结论
Nanog、ZEB1 和 EpCAM 的上调可能促进 SOC 的侵袭性生长，复发风险高，对标准化疗方案反应不良。
Zotero 插件